Core Laboratories (NYSE:CLB) Updates Q4 2025 Earnings Guidance

Key Points

• Core Laboratories has updated its earnings guidance for Q4 2025, projecting earnings per share between 0.180 and 0.22, which is slightly above the consensus estimate of 0.190.
• The company anticipates revenue of $132.0 million-$136.0 million, exceeding the consensus forecast of $127.9 million.
• Several analysts have rated Core Laboratories stock as a "hold," with a consensus price target set at $12.50, reflecting mixed outlooks amidst ongoing adjustments in institutional investment positions.

Core Laboratories (NYSE:CLB - Get Free Report) issued an update on its fourth quarter 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 0.180-0.22 for the period, compared to the consensus earnings per share estimate of 0.190. The company issued revenue guidance of $132.0 million-$136.0 million, compared to the consensus revenue estimate of $127.9 million.

Core Laboratories Stock Performance

CLB stock traded up $0.77 during trading hours on Wednesday, reaching $12.81. The stock had a trading volume of 542,933 shares, compared to its average volume of 477,589. The stock has a market capitalization of $600.66 million, a PE ratio of 20.66, a price-to-earnings-growth ratio of 6.55 and a beta of 1.38. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.27 and a quick ratio of 1.70. The stock has a 50-day simple moving average of $11.77 and a 200 day simple moving average of $11.74. Core Laboratories has a fifty-two week low of $9.72 and a fifty-two week high of $21.83.

Core Laboratories (NYSE:CLB - Get Free Report) last announced its quarterly earnings results on Wednesday, October 22nd. The oil and gas company reported $0.22 EPS for the quarter, beating analysts' consensus estimates of $0.18 by $0.04. Core Laboratories had a net margin of 5.73% and a return on equity of 14.15%. Core Laboratories has set its Q4 2025 guidance at 0.180-0.22 EPS. Analysts predict that Core Laboratories will post 0.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CLB has been the subject of a number of research reports. Wall Street Zen upgraded shares of Core Laboratories from a "sell" rating to a "hold" rating in a research note on Saturday, July 26th. Stifel Nicolaus cut their target price on shares of Core Laboratories from $13.00 to $12.00 and set a "hold" rating for the company in a research note on Wednesday, July 16th. Weiss Ratings restated a "sell (d+)" rating on shares of Core Laboratories in a research note on Wednesday, October 8th. Finally, Zacks Research upgraded shares of Core Laboratories from a "strong sell" rating to a "hold" rating in a research note on Friday, August 15th. Three equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Reduce" and a consensus price target of $12.50.

Hedge Funds Weigh In On Core Laboratories

Hedge funds and other institutional investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC raised its position in shares of Core Laboratories by 400.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,333 shares of the oil and gas company's stock valued at $84,000 after buying an additional 5,869 shares in the last quarter. Brevan Howard Capital Management LP acquired a new position in shares of Core Laboratories in the 2nd quarter valued at approximately $189,000. Quantbot Technologies LP raised its position in shares of Core Laboratories by 343.7% in the 2nd quarter. Quantbot Technologies LP now owns 17,520 shares of the oil and gas company's stock valued at $202,000 after buying an additional 13,571 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Core Laboratories by 6.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 17,932 shares of the oil and gas company's stock valued at $207,000 after buying an additional 1,040 shares in the last quarter. Finally, Sei Investments Co. acquired a new position in shares of Core Laboratories in the 2nd quarter valued at approximately $231,000. 97.81% of the stock is currently owned by institutional investors and hedge funds.

Core Laboratories Company Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.